1. Home
  2. Labeler Index
  3. Physicians Total Care, Inc.
  4. 54868-6104
  5. Product Images: Losartan Potassium

Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Losartan Potassium NDC 54868-6104 by Physicians Total Care, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Losartan Potassium Tablets USP 50 mg Label - 6104

Losartan Potassium Tablets USP 50 mg Label - 6104

This is a label of Losartan Potassium 584g distributed by Physicians Total Care. It contains the NDC code 54868-6104-0, lot number q080, and an expiration date of 61460. The rest of the text is not legible or recognizable.*

Losartan Potassium Tablets USP 100 mg Label - 6107

Losartan Potassium Tablets USP 100 mg Label - 6107

This is a medication distributed by Physicians Total Care with an NDC code of 54868-6107-0. The name of the medication is "LOSHRTAN POTASSIU 160G" and it appears to come in a quantity of 600. However, the remaining characters are not legible and do not provide any additional information.*

Losartan Potassium Tablets USP 25 mg Label - 6117

Losartan Potassium Tablets USP 25 mg Label - 6117

Chem Structure for losartan potassium - b0445fa2 0e1a 4978 b49a b52fd494d568 01

Chem Structure for losartan potassium - b0445fa2 0e1a 4978 b49a b52fd494d568 01

FIgure 1 - b0445fa2 0e1a 4978 b49a b52fd494d568 02

FIgure 1 - b0445fa2 0e1a 4978 b49a b52fd494d568 02

This appears to be a comparison of two drugs, Atenolol and Losartan potassium, in terms of their impact on a primary endpoint in a group of patients. The percentage of patients experiencing the endpoint is not provided, but a risk reduction of 13% was observed in the group receiving Losartan potassium, with a p-value of 0.021 indicating statistical significance. The data is presented over a 66-month study period.*

Figure 2 - b0445fa2 0e1a 4978 b49a b52fd494d568 03

Figure 2 - b0445fa2 0e1a 4978 b49a b52fd494d568 03

The text provided shows data related to a study comparing the effectiveness of two drugs, Atenolol and Losartan potassium, in reducing the risk of fatal or non-fatal stroke in patients. The study shows an adjusted risk reduction of 25% with a p-value of 0.001. There is a graph displaying the study month and the percentage of patients with stroke over time.*

Figure 3 - b0445fa2 0e1a 4978 b49a b52fd494d568 04

Figure 3 - b0445fa2 0e1a 4978 b49a b52fd494d568 04

Figure 4 - b0445fa2 0e1a 4978 b49a b52fd494d568 05

Figure 4 - b0445fa2 0e1a 4978 b49a b52fd494d568 05

The text provides information on a study or clinical trial that involved patients experiencing an event. The study compared the use of Losartan Potassium with the use of Placebo over a period of 24 months, with follow-up measurements taken at 36 and 48 months. The study found that the Risk Reduction with Losartan Potassium was 16.1% compared to Placebo, with a p-value of 0.022. This information could be useful for medical professionals and researchers interested in the efficacy of Losartan Potassium in managing events in patients.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.